Syros starts dosing in Phase I trial of SY-1365 to treat solid tumours

US-based biopharmaceutical company Syros Pharmaceuticals has started dosing patients in its Phase I clinical trial of SY-1365 for the treatment of patients with advanced solid tumours.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news